Novo Nordisk shares slide after guidance disappoints investors - cnbc.com

Core Impact Points

• Novo Nordisk's shares fell after the company's guidance disappointed investors.
• The company's Q2 earnings beat expectations, driven by soaring GLP-1 sales.
• Novo Nordisk raised its full-year outlook, citing strong demand for its diabetes and obesity treatments.
• The company's GLP-1 sales have been a key driver of its growth, with Wegovy being a top-selling medication.
• Novo Nordisk's Q2 earnings report highlights the growing demand for diabetes and obesity treatments in the US market.
• The company's stock performance may be influenced by the US market's response to its guidance and earnings report.